The anthracycline therapy‐related AMLs (t‐AMLs) frequently exhibit balanced chromosomal translocations at 11q23 (involving MLL1 gene) or 21q22 (involving AML1/RUNX1/CBFA2 gene), however occurring at unique breakpoints than de novo AML with the same cytogenetics [101, 102, 103, 104]. Here, RUNX1 is linked to acute myeloid leukemia.